Published on 28 Jul 2023 on Insider Monkey via Yahoo Finance

Is it Still Worthy to Invest in Adaptive Biotechnologies (ADPT)?

Aristotle Atlantic Partners, an investment management firm, released its second quarter 2023 investor letter, a copy of which can be downloaded here. For the second quarter of 2023, Aristotle Atlantic’s Core Equity Composite posted a total return of 9.29 % gross of fees (9.18% net of fees), outperforming the S&P 500 Index, which recorded a total return of 8.74%. Spare some time to check the fund’s top 5 holdings to know more about their top bets for 2023.

In its Q2 2023 investor letter, Aristotle Atlantic Partners mentioned Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and explained its insights for the company. Founded in 2009, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a Seattle, Washington-based biotech company with a $1.1 billion market capitalization. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) delivered a 5.63% return since the beginning of the year, while its 12-month returns are down by -11.90%. The stock closed at $8.07 per share on July 28, 2023.

Here is what Aristotle Atlantic Partners has to say about Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in its Q2 2023 investor letter: